Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

Shien, Tadahiko; Iwata, Hiroji; Aogi, Kenjiro; Fukutomi, Takashi; Inoue, Kentaro; Kinoshita, Takayuki; Takahashi, Masato; Matsui, Akira; Shibata, Taro; Fukuda, Haruhiko

doi:10.1007/s10147-013-0657-z

Cited by 9 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daunorubicin in injectable form was introduced as a chemotherapy drug for different types of cancers, such as chronic and acute myelogenous leukemia and breast cancer (Skovsgaard, 1978;Slater et al, 1982;Raut, 2015). Daunorubicin, commonly prescribed in combination with other anticancer drugs in chemotherapy, such as tamoxifen, is used to reduce the side effects of surgery and the reinfection risk of breast cancer (Reiffers et al, 1996;Guo and Lu, 2010;Shien et al, 2014). Numerous studies have investigated the effects and benefits of the simultaneous use of daunorubicin and tamoxifen on the human body (Shao et al, 2012;Li et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Evaluation of Pt,Pd-Doped, NiO-Decorated, Single-Wall Carbon Nanotube-Ionic Liquid Carbon Paste Chemically Modified Electrode: An Ultrasensitive Anticancer Drug Sensor for the Determination of Daunorubicin in the Presence of Tamoxifen

et al. 2020

View full text Add to dashboard Cite

Measuring the concentration of anticancer drugs in pharmacological and biological samples is a very useful solution to investigate the effectiveness of these drugs in the chemotherapy process. A Pt,Pd-doped, NiO-decorated SWCNTs (Pt,Pd-NiO/SWCNTs) nanocomposite was synthesized using a one-pot procedure and combining chemical precipitation and ultrasonic sonochemical methods and subsequently characterized by TEM and EDS analysis methods. The analyses results showed the high purity and good distribution of elements and the ~10-nm diameter of the Pt,Pd-NiO nanoparticle decorated on the surface of the SWCNTs with a diameter of about 20–30 nm. Using a combination of Pt,Pd-NiO/SWCNTs and 1-butyl-2,3-dimethylimidazolium tetrafluoroborate (1B23DTFB) in a carbon paste (CP) matrix, Pt,Pd-NiO/SWCNTs/1B23DTFB/CP was fabricated as a highly sensitive analytical tool for the electrochemical determination of daunorubicin in the concentration range of 0.008–350 μM with a detection limit of 3.0 nM. Compared to unmodified CP electrodes, the electro-oxidation process of daunorubicin has undergone significant improvements in current (about 9.8 times increasing in current) and potential (about 110 mV) decreasing in potential). It is noteworthy that the designed sensor can well measure daunorubicin in the presence of tamoxifen (two breast anticancer drugs with a ΔE = 315 mV. According to the real sample analysis data, the Pt,Pd-NiO/SWCNTs/1B23DTFB/CP has proved to be a promising methodology for the analysis and measuring of daunorubicin and tamoxifen in real (e.g., pharmaceutical) samples.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Evaluation of Pt,Pd-Doped, NiO-Decorated, Single-Wall Carbon Nanotube-Ionic Liquid Carbon Paste Chemically Modified Electrode: An Ultrasensitive Anticancer Drug Sensor for the Determination of Daunorubicin in the Presence of Tamoxifen

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Preventing metastasis is hampered by limited treatment options. TAM is an ER antagonist, mainly used in ER + breast cancers through ER-dependent mechanism with definitive efficacy [9–11, 19, 26–31], and is thus much less efficacious in ER − breast cancers, such as TNBC [32]. Recently, TAM showed broad-spectrum antitumor properties in ER − cancers, such as gastric cancer, colorectal cancer and cholangiocarcinoma [33].…”

Section: Discussionmentioning

confidence: 99%

Tamoxifen reverses epithelial–mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells

Wang

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundAlthough the efficacy of tamoxifen (TAM) for breast cancer has been attributed to inducing cell cycle arrest and apoptosis by inhibiting estrogen receptor (ER) signaling, recent evidence indicates that TAM also possesses ER-independent antitumor activity through an unclear mechanism. The present study investigated the anti-tumor mechanism of TAM on mesenchymal triple-negative breast cancer (TNBC).MethodsThe inhibitory effect of TAM on tumor migration and metastasis was analyzed by transwell chamber in vitro and by murine xenograft model in vivo. The promoter sequence of miR-200c was predicted by an online CpG island predictor. Relative expression of miR-200c was measured by quantitative real-time PCR.ResultsAfter treatment with TAM, mesenchymal TNBC cells (MCF-7/ADR and MDA-MB-231) morphologically changed from mesenchymal to epithelial types. Meanwhile, cell migration ability was also significantly decreased in ER-positive breast cancer cells after exposure to TAM. Consistent with these in-vitro results, TAM significantly suppressed lung metastasis rate of mesenchymal TNBC cells in murine xenograft tumors. miRNA array analysis of two types of breast cancer cells showed that miR-200c expression was inhibited in mesenchymal TNBC cells, but increased after TAM treatment due to demethylation of miR-200c promoters.ConclusionsOur results indicate that TAM inhibits cell migration and enhances chemosensitivity of mesenchymal TNBC cells by reversing their EMT-like property; and that this EMT-reversal effect results from upregulation of miR-200c through demethylating its promoter. To our knowledge, this is the first explanation of a non-ER-related mechanism for the effect of TAM on mesenchymal TNBC cells.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3457-4) contains supplementary material, which is available to authorized users.

show abstract

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

Shien

Iwata

Fukutomi

et al. 2014

Cancer Chemother Pharmacol

Self Cite

View full text Add to dashboard Cite

PurposeA prospective randomized clinical trial was conducted to evaluate the efficacy of tamoxifen plus doxorubicin and cyclophosphamide compared to tamoxifen plus tegafur-uracil as an adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC).MethodsEligibility criteria included pathologically node-positive (n = 1–9) preMBC with curative resection, in stages I–IIIA. Patients were randomized to receive either tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU) for 2 years or six courses of a 28-day cycle of doxorubicin 40 mg/m2 plus cyclophosphamide 500 mg/m2 on day 1 along with tamoxifen (ACT) given for 2 years as adjuvant therapy. Primary endpoint was overall survival (OS), and secondary endpoint was recurrence-free survival (RFS).ResultsIn total, 169 patients were recruited (TU arm 87, ACT arm 82) between October 1994 and September 1999. The HR for OS was 0.76 (95 % CI 0.35, 1.66, log-rank p = 0.49) and that for RFS was 0.77 (95 % CI 0.44, 1.36, log-rank p = 0.37), with ACT resulting in a better HR. The 5-year OS was 79.7 % for patients in the TU arm and 83 % for those in the ACT arm. The 5-year RFS was 66.1 % for patients in the TU arm and 70.6 % for those in the ACT arm. A higher proportion of patients in the ACT arm experienced grade 3 leucopenia (0 % in the TU arm, 4 % in the ACT arm).ConclusionsThere were no significant differences in the efficacy of TU and ACT as adjuvant therapy.

show abstract

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

Abstract: The efficacy of adding AC to TAM was not high for ER+, node-positive PMBC. However, adjuvant ACT therapy was considered to be effective for ER-, node-positive PMBC.

Cited by 9 publications

References 20 publications

RETRACTED: Evaluation of Pt,Pd-Doped, NiO-Decorated, Single-Wall Carbon Nanotube-Ionic Liquid Carbon Paste Chemically Modified Electrode: An Ultrasensitive Anticancer Drug Sensor for the Determination of Daunorubicin in the Presence of Tamoxifen

RETRACTED: Evaluation of Pt,Pd-Doped, NiO-Decorated, Single-Wall Carbon Nanotube-Ionic Liquid Carbon Paste Chemically Modified Electrode: An Ultrasensitive Anticancer Drug Sensor for the Determination of Daunorubicin in the Presence of Tamoxifen

Tamoxifen reverses epithelial–mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

Contact Info

Product

Resources

About